Literature DB >> 22641398

Genetic modifiers of sickle cell disease.

Martin H Steinberg1, Paola Sebastiani.   

Abstract

Sickle cell anemia is associated with unusual clinical heterogeneity for a Mendelian disorder. Fetal hemoglobin concentration and coincident α thalassemia, both which directly affect the sickle erythrocyte, are the major modulators of the phenotype of disease. Understanding the genetics underlying the heritable subphenotypes of sickle cell anemia would be prognostically useful, could inform personalized therapeutics, and might help the discovery of new "druggable" pathophysiologic targets. Genotype-phenotype association studies have been used to identify novel genetic modifiers. In the future, whole genome sequencing with its promise of discovering hitherto unsuspected variants could add to our understanding of the genetic modifiers of this disease.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22641398      PMCID: PMC4562292          DOI: 10.1002/ajh.23232

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  152 in total

Review 1.  Predicting clinical severity in sickle cell anaemia.

Authors:  M H Steinberg
Journal:  Br J Haematol       Date:  2005-05       Impact factor: 6.998

2.  Two different forms of homozygous sickle cell disease occur in Saudi Arabia.

Authors:  M A Padmos; G T Roberts; K Sackey; A Kulozik; S Bail; J S Morris; B E Serjeant; G R Serjeant
Journal:  Br J Haematol       Date:  1991-09       Impact factor: 6.998

Review 3.  The multifunctional role of EKLF/KLF1 during erythropoiesis.

Authors:  Miroslawa Siatecka; James J Bieker
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

4.  Genetic polymorphism of the mannose-binding protein gene in children with sickle cell disease: identification of three new variant alleles and relationship to infections.

Authors:  M G Neonato; C Y Lu; M Guilloud-Bataille; C Lapouméroulie; H Nabeel-Jassim; D Dabit; R Girot; R Krishnamoorthy; J Feingold; C Besmond; J Elion
Journal:  Eur J Hum Genet       Date:  1999-09       Impact factor: 4.246

5.  Hemolysis-associated priapism in sickle cell disease.

Authors:  Vikki G Nolan; Diego F Wyszynski; Lindsay A Farrer; Martin H Steinberg
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

6.  The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Antonios Bilalis; Eleni Plata; Konstantinos Varvagiannis; George Stamatopoulos; Klio Sinopoulou; Aggeliki Balassopoulou; Dimitris Loukopoulos; Evangelos Terpos
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

7.  Beta-S gene cluster haplotypes modulate hematologic and hemorheologic expression in sickle cell anemia. Use in predicting clinical severity.

Authors:  D R Powars; H J Meiselman; T C Fisher; A Hiti; C Johnson
Journal:  Am J Pediatr Hematol Oncol       Date:  1994-02

8.  Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease.

Authors:  S A Zimmerman; R E Ware
Journal:  Am J Hematol       Date:  1998-12       Impact factor: 10.047

9.  Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality.

Authors:  D R Powars; D D Elliott-Mills; L Chan; J Niland; A L Hiti; L M Opas; C Johnson
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

10.  G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia.

Authors:  Françoise Bernaudin; Suzanne Verlhac; Sylvie Chevret; Martine Torres; Lena Coic; Cécile Arnaud; Annie Kamdem; Isabelle Hau; Maria Grazia Neonato; Christophe Delacourt
Journal:  Blood       Date:  2008-09-04       Impact factor: 22.113

View more
  90 in total

1.  SIRT1 activates the expression of fetal hemoglobin genes.

Authors:  Yan Dai; Tyngwei Chen; Heba Ijaz; Elizabeth H Cho; Martin H Steinberg
Journal:  Am J Hematol       Date:  2017-08-28       Impact factor: 10.047

2.  Genetic modulation of fetal hemoglobin in hydroxyurea-treated sickle cell anemia.

Authors:  Milena Magalhães Aleluia; Rayra Pereira Santiago; Caroline Conceição da Guarda; Teresa Cristina Cardoso Fonseca; Fábia Idalina Neves; Regiana Souza Quinto; Camylla Villas Boas Figueiredo; Sètondji Cocou Modeste Alexandre Yahouédéhou; Rodrigo Mota Oliveira; Júnia Raquel Dutra Ferreira; Bruno Antônio Veloso Cerqueira; Cynara Gomes Barbosa; Jacqueline Nicole Milton; Martin H Steinberg; Marilda de Souza Gonçalves
Journal:  Am J Hematol       Date:  2017-03-10       Impact factor: 10.047

Review 3.  Gene therapy for sickle cell disease: An update.

Authors:  Selami Demirci; Naoya Uchida; John F Tisdale
Journal:  Cytotherapy       Date:  2018-05-30       Impact factor: 5.414

4.  Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia.

Authors:  G Lucarelli; A Isgrò; P Sodani; M Marziali; J Gaziev; K Paciaroni; C Gallucci; L Cardarelli; M Ribersani; C Alfieri; G De Angelis; D Armiento; M Andreani; M Testi; A Amato; O O Akinyanju; T T Wakama
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

Review 5.  Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Authors:  Ram Kalpatthi; Enrico M Novelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

6.  Alpha thalassemia, but not βS-globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort.

Authors:  Betânia Lucena Domingues Hatzlhofer; Diego Antonio Pereira-Martins; Igor de Farias Domingos; Gabriela da Silva Arcanjo; Isabel Weinhäuser; Diego Arruda Falcão; Isabela Cristina Cordeiro Farias; Jéssica Vitória Gadelha de Freitas Batista; Luana Priscilla Laranjeira Prado; Jéssica Maria Florencio Oliveira; Thais Helena Chaves Batista; Marcondes José de Vasconcelos Costa Sobreira; Rodrigo Marcionilo de Santana; Amanda Bezerra de Sá Araújo; Manuela Albuquerque de Melo; Bruna Vasconcelos de Ancântara; Juan Luiz Coelho-Silva; Ana Beatriz Lucas de Moura Rafael; Danízia Menezes de Lima Silva; Flávia Peixoto Albuquerque; Magnun Nueldo Nunes Santos; Ana Cláudia Dos Anjos; Fernando Ferreira Costa; Aderson da Silva Araújo; Antonio Roberto Lucena-Araújo; Marcos André Cavalcanti Bezerra
Journal:  Ann Hematol       Date:  2021-02-13       Impact factor: 3.673

7.  Interventions for chronic kidney disease in people with sickle cell disease.

Authors:  Noemi Ba Roy; Patricia M Fortin; Katherine R Bull; Carolyn Doree; Marialena Trivella; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-10

8.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2016-10

Review 9.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2017-05-13

Review 10.  Genetic Network Complexity Shapes Background-Dependent Phenotypic Expression.

Authors:  Jing Hou; Jolanda van Leeuwen; Brenda J Andrews; Charles Boone
Journal:  Trends Genet       Date:  2018-06-11       Impact factor: 11.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.